Main Article Content
Abstract
Background: Heart failure is a major health problem in the world. It is associated with high morbidity and high mortality especially in elderly patients. Most studies reported using N terminal pro-B type natriuretic peptide (NT-proBNP) in diagnosis of heart failure, but about of these tests in determining classification of severity of heart failure in the elderly remain unclear.
Objective: To determine the differences NT-pro BNP levels based on the severity of diease of heart failure in elderly patients.
Methods: This is an observational study with cross sectional design. Subjects were patients with diagnosed heart failure and aged = 60 years. Patients were divided into two groups, mild and severe heart failure groups according to severity of heart failure in New York Heart Association (NYHA) class. The NT Pro-BNP levels were measured for all subjects in both groups. Data was analyzed with using unpaired t test and was considered significant if p <0.05.
Results: This study involved 24 subjects, consisting of 2 gorups, there were mild heart failure groups (NYHA class I-II) and groups of patients with severe heart failure (NYHA III-IV). The mean age of the subjects was 64.50 ± 4.65 years with a minimum age of 60 years and a maximum of 78 years. The NT pro-BNP levels in the severe heart failure group (1.2587.58 ± 574.85 pg / ml) was higher than the mild heart failure group (867.83 ± 333.27 pg / ml), it was statistically significant with p = 0.040.
Conclusion: The levels of NT-pro BNP serum in elderly patients with severe heart failure (NYHA III-IV) were significantly higher than in patients with mild heart failure (NYHA I-II).
Keywords
Article Details
Authors who publish in the Jurnal Kedokteran dan Kesehatan Indonesia agree to the following terms:
- Authors retain copyright and grant Jurnal Kedokteran dan Kesehatan Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution Licence that allows others to adapt (remix, transform, and build) upon the work non-commercially with an acknowledgement of the work's authorship and initial publication in Jurnal Kedokteran dan Kesehatan Indonesia.
- Authors are permitted to share (copy and redistribute) the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Jurnal Kedokteran dan Kesehatan Indonesia.
References
- RISKESDAS. Riset Kesehatan Dasar 2018. Kementrian Kesehatan Republik Indonesia. 2018.
- Danielsen R, Thorgeirsson G, Einarsson H, Ólafsson Ö, Aspelund T, Harris TB, et al. Prevalence of heart failure in the elderly and future projections: the AGES-Reykjavík study. Scand Cardiovasc J. 2017;51(4):183–9.
- Lilly LS. Pathophysiology of heart disease: A collaborative project of medical students and faculty: Fifth edition. Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty: Fifth Edition. 2013.
- Januzzi JL. Natriuretic peptides as biomarkers in heart failure. In: Journal of Investigative Medicine. 2013.
- Isbandiyah. Brain natriuretic peptide. ejournal.umm.ac.id [Internet]. 2011;7(15):37–47. Available from: http://ejournal.umm.ac.id/index.php/sainmed/article/viewFile/4076/4454
- De Boer RA, Nayor M, DeFilippi CR, Enserro D, Bhambhani V, Kizer JR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018;3(3):215–24.
- Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJV, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: Systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.
- Sokhanvar S, Shekhi M, Mazlomzadeh S, Golmohammadi Z. The Relationship between Serum NT- Pro-BNP Levels and Prognosis in Patients with Systolic Heart Failure. J Cardiovasc Thorac Res. 2011;3(2):57–61.
- Alhusseiny AH, Al-Nimer MSM, Latif II, Ibrahim AK. Heart failure: Discrepancy between NYHA functional classification, serum NT-pro brain natriuretic peptide and ejection fraction. Eur J Gen Med. 2013;10(1):26–31.
- Fabbian F, De Giorgi A, Pala M, Tiseo R, Portaluppi F. Elevated NT-proBNP levels should be interpreted in elderly patients presenting with dyspnea. Eur J Intern Med. 2011;22(1):108–11.
- Plichart M, Orvoën G, Jourdain P, Quinquis L, Coste J, Escande M, et al. Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study. Eur J Heart Fail. 2017;19(4):540–8.
- Sarzani R, Spannella F, Giulietti F, Fedecostante M, Giordano P, Gattafoni P, et al. NT-proBNP and its correlation with in-hospital mortality in the very elderly without an admission diagnosis of heart failure. PLoS One [Internet]. 2016;1–12. Available from: https://doi.org/10.1371/journal.pone.0153759
- Sopiyudin Dahlan M. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan. Epidemiologi Indonesia. 2016.
- Reinardi R. Hubungan Nilai N -Terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) dengan Keparahan Penderita Gagal Jantung [Internet]. Tesis. Universitas Sumatra Utara; 2009. Available from: http://repository.usu.ac.id/bitstream/handle/123456789/6321/09E00796.pdf?sequence=1
- Hartoto HH, Zulkarnain BS, Aminuddin M. ANALYSIS OF CHANGES IN THE SERUM LEVEL NT-proBNP AFTER ACE INHIBITORS THERAPY IN PATIENTS WITH HEART FAILURE. Folia Medica Indones. 2017;52(3):193.
- Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart. 2003;89(7):745–51.
- Vergaro G, Januzzi JL, Cohen Solal A, Aimo A, Arzilli C, Zyw L, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018;271:324–30.
- Vaes B, Delgado V, Bax J, Degryse J, Westendorp RG, Gussekloo J. Diagnostic accuracy of plasma NT-proBNP levels for excluding cardiac abnormalities in the very elderly. BMC Geriatr. 2010;
- Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal ProB-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881–9.
- Belagavi AC, Rao M, Pillai AY, Srihari US. Correlation between NT proBNP and left ventricular ejection fraction in elderly patients presenting to emergency department with dyspnoea. Indian Heart J. 2012;64(3):302–4.
- Djami SW, Arif M, Bahrun U. N Terminal-Pro Brain Natriuretic Peptide (Nt–ProBNP) Pada Penderita Hipertensi Derajat 1 Dan Derajat 2. J Info Kesehat. 2019;17(1):63–73.
- Bower JK, Lazo M, Matsushita K, Rubin J, Hoogeveen RC, Ballantyne CM, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) and risk of hypertension in the Atherosclerosis Risk in Communities (ARIC) study. Am J Hypertens. 2015;28(10):1262–6.
References
RISKESDAS. Riset Kesehatan Dasar 2018. Kementrian Kesehatan Republik Indonesia. 2018.
Danielsen R, Thorgeirsson G, Einarsson H, Ólafsson Ö, Aspelund T, Harris TB, et al. Prevalence of heart failure in the elderly and future projections: the AGES-Reykjavík study. Scand Cardiovasc J. 2017;51(4):183–9.
Lilly LS. Pathophysiology of heart disease: A collaborative project of medical students and faculty: Fifth edition. Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty: Fifth Edition. 2013.
Januzzi JL. Natriuretic peptides as biomarkers in heart failure. In: Journal of Investigative Medicine. 2013.
Isbandiyah. Brain natriuretic peptide. ejournal.umm.ac.id [Internet]. 2011;7(15):37–47. Available from: http://ejournal.umm.ac.id/index.php/sainmed/article/viewFile/4076/4454
De Boer RA, Nayor M, DeFilippi CR, Enserro D, Bhambhani V, Kizer JR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018;3(3):215–24.
Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJV, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: Systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.
Sokhanvar S, Shekhi M, Mazlomzadeh S, Golmohammadi Z. The Relationship between Serum NT- Pro-BNP Levels and Prognosis in Patients with Systolic Heart Failure. J Cardiovasc Thorac Res. 2011;3(2):57–61.
Alhusseiny AH, Al-Nimer MSM, Latif II, Ibrahim AK. Heart failure: Discrepancy between NYHA functional classification, serum NT-pro brain natriuretic peptide and ejection fraction. Eur J Gen Med. 2013;10(1):26–31.
Fabbian F, De Giorgi A, Pala M, Tiseo R, Portaluppi F. Elevated NT-proBNP levels should be interpreted in elderly patients presenting with dyspnea. Eur J Intern Med. 2011;22(1):108–11.
Plichart M, Orvoën G, Jourdain P, Quinquis L, Coste J, Escande M, et al. Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study. Eur J Heart Fail. 2017;19(4):540–8.
Sarzani R, Spannella F, Giulietti F, Fedecostante M, Giordano P, Gattafoni P, et al. NT-proBNP and its correlation with in-hospital mortality in the very elderly without an admission diagnosis of heart failure. PLoS One [Internet]. 2016;1–12. Available from: https://doi.org/10.1371/journal.pone.0153759
Sopiyudin Dahlan M. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan. Epidemiologi Indonesia. 2016.
Reinardi R. Hubungan Nilai N -Terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) dengan Keparahan Penderita Gagal Jantung [Internet]. Tesis. Universitas Sumatra Utara; 2009. Available from: http://repository.usu.ac.id/bitstream/handle/123456789/6321/09E00796.pdf?sequence=1
Hartoto HH, Zulkarnain BS, Aminuddin M. ANALYSIS OF CHANGES IN THE SERUM LEVEL NT-proBNP AFTER ACE INHIBITORS THERAPY IN PATIENTS WITH HEART FAILURE. Folia Medica Indones. 2017;52(3):193.
Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart. 2003;89(7):745–51.
Vergaro G, Januzzi JL, Cohen Solal A, Aimo A, Arzilli C, Zyw L, et al. NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. Int J Cardiol. 2018;271:324–30.
Vaes B, Delgado V, Bax J, Degryse J, Westendorp RG, Gussekloo J. Diagnostic accuracy of plasma NT-proBNP levels for excluding cardiac abnormalities in the very elderly. BMC Geriatr. 2010;
Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal ProB-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881–9.
Belagavi AC, Rao M, Pillai AY, Srihari US. Correlation between NT proBNP and left ventricular ejection fraction in elderly patients presenting to emergency department with dyspnoea. Indian Heart J. 2012;64(3):302–4.
Djami SW, Arif M, Bahrun U. N Terminal-Pro Brain Natriuretic Peptide (Nt–ProBNP) Pada Penderita Hipertensi Derajat 1 Dan Derajat 2. J Info Kesehat. 2019;17(1):63–73.
Bower JK, Lazo M, Matsushita K, Rubin J, Hoogeveen RC, Ballantyne CM, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) and risk of hypertension in the Atherosclerosis Risk in Communities (ARIC) study. Am J Hypertens. 2015;28(10):1262–6.